Zentalis Pharmaceuticals (ZNTL) EBIT Margin (2024)
Zentalis Pharmaceuticals (ZNTL) posted quarterly EBIT Margin of 185.55% for Q4 2024, down 203.9% quarter-over-quarter from 61.06% in Q1 2024.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) EBIT Margin (2024) Analysis & Trends
Zentalis Pharmaceuticals' EBIT Margin history runs 1 years deep, the most recent figure standing at 185.55% for Q4 2024.
- In Q4 2024, EBIT Margin changed N/A year-over-year to 185.55%; the TTM figure through Sep 2025 stood at 615.16% (down 9922.0% YoY), while the FY2024 annual figure was 283.57%, changed N/A from the prior year.
- EBIT Margin for Q4 2024 stood at 185.55%, down from 61.06% in the prior quarter.
- The five-year high for EBIT Margin was 61.06% in Q1 2024, with the low at 185.55% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | - |